Psyence Biomedical Ltd. (PBMWW) stock
PBMWWNasdaqPharmaceutical PreparationsFiscal year ends March 31Also trades as PBM
$0.01−0.00 (-2.50%)
Close on Oct 30, 2026Market cap –P/E –Yield –
Psyence Biomedical EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2026 it was -$12.56, down 138.3% from the year before.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -$12.56 | -138.3% |
| FY2025 | Mar 31, 2025 | $32.76 | – |
| FY2024 | Mar 31, 2024 | -$29214.06 | – |
| FY2023 | Mar 31, 2023 | -$2462.88 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Sep 30, 2025 | -$3.19 | – |
| Q2 FY2025 | Sep 30, 2024 | $25.44 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics